Sana Biotechnology, Inc. — Director's Dealing 2021

Feb 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Sana Biotechnology, Inc. (SANA)
CIK: 0001770121
Period of Report: 2021-02-08

Reporting Person: Harr Steve (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-08	Common Stock	C	2031250	—	Acquired	8173750	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-08	Series A-1 Convertible Preferred Stock	$	C	1075000	Disposed		Common Stock (1075000)	Direct
2021-02-08	Series A-2 Convertible Preferred Stock	$	C	800000	Disposed		Common Stock (800000)	Direct
2021-02-08	Series B Convertible Preferred Stock	$	C	156250	Disposed		Common Stock (156250)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	682500	Indirect

Footnotes

F1: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering.

F2: The expiration date is not relevant to the conversion of these securities.